Effect of oxprenolol on ventricular arrhythmias: The european infarction study experience  by Bethge, Klaus-Peter et al.
JACC Vol. 6, NO.5 
November 1985:963-72 
963 
Effect of Oxprenolol on Ventricular Arrhythmias: The European 
Infarction Study Experience 
KLAUS-PETER BETHGE, MD,* DIETRICH ANDRESEN, MD,t JEAN-PIERRE BOISSEL, MD,:j: 
ENZ-RUDIGER VON LEITNER, MD, t JEAN-CLAUDE PEYRIEUX, MSc,:j: 
ROLF SCHRODER, MD, FACC,t ULRICH TIETZE, MSc,t 
FOR THE EUROPEAN INFARCTION STUDY GRoupll 
In 736 patients, 24 hour electrocardiographic recordings 
were performed 14 to 36 days after acute myocardial 
infarction before the start of randomized treatment with 
320 mg of slow release oxprenolol (n = 358) or placebo 
(n = 378). Follow-up 24 hour electrocardiographic re•
cordings were obtained 5 to 12 days (median 10) and 
3, 6 and 12 months after the first administration of the 
study medication. Oxprenolol-treated patients had a sig•
nificantly lower daytime heart rate as compared with 
the placebo group, whereas no difference was found at 
night. At baseline, 22.1 % of the patients allocated to 
oxprenolol treatment and 29.6% of the placebo group 
had more than 30 ventricular extrasystoles in 1 hour at 
least once during 24 hour monitoring; nlUltiform ven•
tricular extrasystoles were present in 58.4 and 62.7%, 
ventricular couplets in 29.6 and 33.9% and ventricular 
tachycardia (3 or more consecutive ventricular extra-
By now, 16 randomized trials of various beta-receptor blocking 
drugs, administered orally a few days or weeks after myo•
cardial infarction, have been completed involving more than 
17,000 patients. Although only some evidenced a statisti•
cally significant reduction in mortality, in general a clear 
trend in favor of beta-receptor blocking treatment is obvious 
(1,2). Patients who survive myocardial infarction are prone 
to sudden cardiac death and, thus, the demonstrated benefit 
in controlled clinical trials of beta-blockers in survivors of 
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systoles) in 21.5 and 20.9% of the oxprenolol-treated 
and placebo-treated patients, respectively. 
During the 1 year follow-up period, the prevalence 
of these arrhythmias did not change significantly in either 
treatment group. There was a trend toward a reduc~ion 
in the daytime frequency of ventricular couplets in the 
oxprenolol group. After 3 and 6 months, only multiform 
ventricular extrasystoles were significantly less frequent 
in the oxprenolol group than in the placebo group (47.4 
and 42.7% versus 59.7 and 57.9%, respectively). Twelve 
months after the acute event, however, multiform ven•
tricular extrasystole frequency was the same in both 
groups of patients (52.1 versus 51.0%, respectively). Thus, 
oxprenolol had a weak suppressant effect on ventricular 
tachyarrhythmias in survivors of myocardial infarction. 
(J Am Coil Cardiol 1985;6:963-72) 
myocardial infarction was mainly related to the reduction 
in the incidence of sudden death. Whether this benefit is 
caused by a primary antiarrhythmic effect mediated through 
the suppression of ventricular tachyarrhythmias is not known. 
This study was done as part of the European Infarction 
Study, which was designed to explore the efficacy of slow 
release oxprenolol on the incidence of total mortality, car•
diac death and nonfatal cardiac events (3,4). There was a 
total 1 year mortality rate of 6.6% in the oxprenolol group 
and 5.1 % in the placebo group. The objective in this study 
was to assess the influence of oxprenolol on heart rate and 
the incidence of cardiac arrhythmias by means of 24 hour 
electrocardiographic recordings at predetermined times 
throughout the study. 
Effects on mortality in selected subgroups in relation to 
various ventricular tachyarrhythmias are not the subject of 
this report. The complexity and the amount of all relevant 
data necessitate that mortality and clinical course be eval•
uated in the subgroups of patients with different clinical 
characteristics. Details on these findings are in preparation. 
0735-1097/85/$3.30 
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Methods 
The European Infarction Study followed a prospective, 
double-blind, placebo-controlled 12 month protocol, de•
scribed in detail recently (3). Findings concerning morbidity 
and mortality in the 1,741 patients of this secondary pre•
vention trial have been published elsewhere (4). 
Patients. Of the 1,741 patients included in the European 
Infarction Study, 949 patients of both sexes, 30 to 69 years 
of age (mean 54), with a diagnosis of acute myocardial 
infarction were considered for investigation by 24 hour con•
tinuous ambulatory electrocardiography during the 1 year 
follow-up period. Of the 57 hospitals participating in the 
study, 33 agreed to recruit patients for this part of the trial. 
To avoid any bias, it was intended to obtain 24 hour electro•
cardiographic recordings from all patients included in the 
European Infarction Study in these hospitals. Yet, in 92 of 
the 949 patients no recording could be obtained, mainly for 
administrative reasons (30 of 768 patients in Germany and 
Switzerland and 62 of 181 in the United Kingdom). These 
92 patients were equally distributed among the two treatment 
groups (50 oxprenolol, 42 placebo). 
In 736 patients, baseline recordings were performed 14 
to 36 days after infarction, 1 day before random allocation 
to treatment with oxprenolol or placebo according to the 
study protocol. Only data from these 736 patients were 
analyzed in this study. After completion of a baseline 24 
hour electrocardiogram, treatment was started with one 160 
mg tablet daily of slow release oxprenolol or matching pla•
cebo for the first 3 days. If no unwanted effects occurred 
during this time, the dose was increased to 160 mg twice 
daily. The second 24 hour electrocardiogram was performed 
in outpatients, that is, in 632 of the 736,5 to 12 days (median 
10) after the start of the study medication intake. The pa•
tients underwent follow-up investigations at 3, 6 and 12 
months after entry into the study, and a 24 hour electro•
cardiogram was obtained in 575, 552 and 499 patients, 
respectively. Complete monitoring, that is, all five 24 hour 
electrocardiograms, was available from 367 patients. Al•
though a relatively high number of patients could not be 
monitored completely because of either lack of patient co•
operation or poor signal quality or insufficient length of the 
recording, a possible bias can be excluded because the in•
completeness of the data was due to technical or adminis•
trative difficulties rather than selection in the hospitals. 
Ambulatory electrocardiography. The incidence of ar•
rhythmias was documented during unrestricted daily activ•
ities using continuous 24 hour electrocardiographic record•
ing (Oxford Medilog 4-24, Abingdon, England). The recorders 
were distributed to the participating hospitals by the Co•
ordinating Centre of the European Infarction Study. To•
gether with identification forms, the 24 hour electrocardio•
graphic cassettes were submitted to three Analyzing Centres, 
two located in the Klinikum Steglitz, Berlin and one in the 
Medizinische HochschuIe, Hannover. 
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The tapes were analyzed by means of a modified (5) 
Pathfinder system (Reynolds Medical, Hertford, England) 
with a proven sensitivity of 95.9%, a positive predictive 
accuracy of 98.6% for ventricular extrasystoles and 93.4% 
sensitivity and a 91.8% positive predictive accuracy for 
consecutive forms of ventricular extrasystoles (couplets or 
ventricular tachycardia, or both) (6). 
In addition, validation of computer-identified couplets 
and ventricular tachycardia was visually made by real-time 
display by the technician and confirmed by the responsible 
cardiologist (for definitions see Table 1). Poly topic origin 
of multiform extrasystoles, identified by continuously ob•
serving the oscilloscope, was assured by careful inspection 
of the electrocardiographic strips containing the question•
able beats. To avoid misinterpretation of aberrantly con•
ducted supraventricular Or fusion beats, the lack of a pre•
ceding P wave and sufficient difference in shape and 
prematurity of the particular beat were considered. Arrhyth•
mias were analyzed in segments of hourly intervals of ar•
tifact-free time as detected by the analyzing system. The 
complete recording was rejected if fewer than 1,.2 segments 
of satisfactory data could be obtained. 
Determination of the mean heart rate was possible by 
dividirtg the total number of beats by the time recorded. To 
assess the influence of study medication on the heart rate 
of one night and two daytime periods, 8 hour periods were 
chosen as a time base, that is, 6 AM to 2 PM, 2 PM to 10 
PM and 10 PM to 6 AM. 
After completion of a 24 hour electrocardiographic anal•
ysis. data tapes and validation forms were mailed to the 
Data Handling and Monitoring Centre (DHMC) in Lyon for 
further processing. Data from the analysis of 24 hour 
electrocardiographic tapes were not disclosed to the phy•
sician in charge of the patient. 
Analysis of data. Analyses were performed on an "in•
tention to treat" basis. In addition, 24 hour electrocardio•
grams from patients "on treatment," that is, before with•
drawal from study medication, were considered separately. 
Ventricular arrhythmias are classified according to av•
erage frequency of ventricular extrasystoles/hour and pres•
ence of 30 or more ventricular extrasystoles/hour at least 
once during 24 hours, multiform ventricular extrasystoles, 
ventricular bigeminy, ventricular couplets and ventricular 
tachycardia (Table 1). 
Since differences in average measures of arrhythmias at 
predetermined times do not consider the individual patient's 
response, longitudinal cohort analyses were performed ad•
ditionally. Two cohorts of patients either with a complete 
first 3 month set of 24 hour electrocardiographic recordings 
(cohort A, 506 patients) or with a complete 12 month follow•
up (cohort B, 367 patients) were evaluated by computing 
the individual patients with "present" or "absent" indexes 
of: 1) at least 1 hour with 30 or more ventricular extrasys•
toles, 2) at least one couplet in 24 houts, 3) one episode of 
ventricular tachycardia in 24 hours, and 4) one couplet or 
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Table 1. Definition of Ventricular Arrhythmias 
Ventricular extrasystole 
Multiform ventricular extrasystole 
Bigeminy 
Couplets 
Ventricular tachycardia 
A beat that is aberrant in shape 
and more than 25% premature 
At least two aberrant beats of 
different shape during the first 
10 hours of recording 
Four normal and three aberrant 
beats in alternating sequence 
Two consecutive aberrant beats 
Three or more consecutive 
aberrant beats (usually three 
to five consecutive beats) 
episode of ventricular tachycardia in 24 hours. An ar•
rhythmic event was considered present when at least one of 
the particular arrhythmias was found on the respective 24 
hour electrocardiographic tape. On this basis, for each of 
the four arrhythmias chosen, groups of patients with dis•
tribution patterns listed in Table 2 were established and 
allocated to three classes of antiarrhythmic efficacy: "im•
provement or possible prevention," "insufficient efficacy" 
and "worsening." 
Statistical analysis. Several statistical test procedures 
have been used according to the problem and the type of 
data considered: chi-square, z test, Wilcoxon-z and analysis 
of variance. Graphic displays were applied for exploratory 
analysis. Because some imbalance was observed among 
groups at baseline, adjusted percentages and statistical tests 
were computed according to the direct as well as the indirect 
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methods (7). The criterion for adjustment was either the 
frequency of the item or the presence or absence of at least 
one tape segment with at least 30 ventricular extrasystoies. 
Results 
The results of this 24 hour electrocardiographic study are 
based on the 736 patients (604 men and 132 women) in 
whom a baseline recording was obtained before random 
allocation to the study medication; 358 patients were treated 
with slow release oxprenolol and 378 with placebo. In the 
oxprenolol group, 22 patients (6.1 %) died during the 1 year 
follow-up period as compared with 17 patients (4.5%) in 
the placebo group. Because these patients were recruited on 
the basis of willingness of the hospital to participate in this 
part of the European Infarction Study rather than by random 
subsampling, and since differences among participating cen•
ters are likely to occur in multicenter trials, the electrocar•
diographic study subgroup cannot be considered represen•
tative of the entire popUlation of the European Infarction 
Study. 
Eighty-seven comparisons of clinical data between the 
two treatment groups were performed. The most important 
are shown in Table 3. Only five yielded a nominal p value 
of 0.1 or less and three yielded a p value of 0.05 or less. 
Under the hypothesis that the two groups were drawn from 
the same popUlation and assuming each comparison to be 
independent (which clearly is not true in every case), chance 
Table 2. Definitions for Three Classes of Antiarrhythmic Efficacy in Two Longitudinal Cohort 
Studies (see also text) 
Cohort A Cohort B 
Day Month Day Month 
Baseline 10 3 10 3 6 12 
Improvement or + + 
possible prevention + + + + 
-* -* 
Insufficient efficacy + + 
+ + 
+ + + + + 
+ + + + + + 
+ + + 
+ + + + 
Worsening + 
+ 
+ + 
+ + + 
+ + + + 
+ + 
+ + + 
*These series were defjned as possible prevention. + = Finding present (that is, the particular arrhythmia 
was found at least once in the reference 24 hour electrocardiogram); - = finding absent, that is, the particular 
arrhythmia was not found in the reference 24 hour electrocardiogram. 
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Table 3. Baseline Comparison of Two Treatment Groups 
Oxprenolol Placebo z or t 
Treatment (n = 358) (n = 378) Value 
Male patients 83.8% 80.4% ~ 1.62 
Mean age (yr) 53.7 54.5 t = ~ 1.32 
Medical history 
Angina pectoris >4 wk* 30.7% 35.4% ~ 1.36 
Previous myocardial infarction 13.4% 16.7% ~ 1.32 
Hypertension 30.7% 30.4% 0.09 
Congestive heart failure 9.5% 11.4% ~0.83 
Diabetes mellitus 10.1% 13.5% ~ 1.44 
Current smoker 62.6% 64.3% ~ l.01 
Clinical data related to acute myocardial 
infarction 
Anterior infarction 40.3% 38.4o/c 0.55 
Lateral infarction 2.8% 4.5% ~ 1.22 
Inferior infarction 47.1% 48.1% ~0.30 
Undefined infarction 9.8% 9.0% 0.38 
Sinus tachycardia (> 100 beats/min) 24.3% 18.5% l.91 
Left heart failure 13.7% 13.2% ~0.18 
Treatment between qualifying myocardial 
infarction and time of randomization 
Beta-receptor blocking drug 13.2% 14.5% ~0.54 
Lidocaine 26.9% 31.0% ~ 1.21 
Other antiarrhythmic agents 5.60/c 6.3% ~0.43 
Inotropic agents 6.7% 6.6% 0.06 
Digitalis 36.4% 37.8% ~0.13 
Diuretic drugs 41.7% 41.3% ~0.13 
Conditions at time of randomization 
Mean heart rate (beats/min) 73.6 73.9 t = ~0.33 
Systolic blood pressure (mm Hg) 127.1 125.4 t = 1.41 
Diastolic blood pressure (mm Hg) 80.5 79.8 t = 0.97 
Ventricular extrasystoles t 7.9% 10.6% ~ 1.26 
Persisting ST elevation 27.3% 24.4% 0.90 
Lung congestion (on X-ray film) 19.1% 28.6% ~3.00 
Cardiothoracic ratio 43.9% 44.4% t = ~0.90 
* A history of angina pectoris was only included for those patients who had symptoms for more than 4 
weeks before infarction to avoid confusion with preinfarction angina; ton standard 12 lead electrocardiogram. 
alone would yield nine differences significant at p = 0, I 
and fourto five differences significant at p = 0.05. There•
fore, with regard to baseline clinical variables, the two groups 
are sufficiently balanced (Table 3). 
Heart rate. Figure I shows the heart rate during the 8 
hour periods at the five predetermined times. Before the 
intake of study medication (baseline), mean day- and night•
time heart rates differed, but there was no difference in heart 
rate between the groups randomized to placebo and ox•
prenolol. Throughout the study, patients receiving oxpreh-
0101 demonstrated a significantly (z value range 3.26 to 
8.95) reduced heart rate during the day (average reduction 
5.9 beats/min [7.5%]). The heart rate at night was not slowed. 
These findings were in contrast to the unchanged circadian 
variations in heart rate throughout the study in the placebo 
group. 
Ventricular extrasystole frequency. Figure 2 shows the 
percent of patients with different frequencies of average 
ventricular extrasystoles/hour for both treatment groups. At 
baseline, 64 (17.9%) of 358 patients randomly ailocated to 
oxprenolol and 87 (23%) of 378 allocated to placebo dem•
onstrated an average of 10 or more ventricular 
extrasystoles/hour. 
No major change in the total incidence andfrequency of 
ventricular extrasystoles was observed during the J year 
follow-up period. When adjusted for baseline, differences 
between both treatment groups remained below statistical 
significance (z value range 1.29 to 0.08). Class 2 criteria 
of the grading scheme proposed by Lown and Wolf (8), that 
is, 30 or more ventricular extrasystoless/hour at least once 
during 24 hours, were fulfilled by 22.1 % of the oxprenolol•
treated patients and by 29.6% of the placebo-treated pa•
tients. There was no significant change throughout the study 
in either group (table 4). 
Qualitative characteristics of ventricular extrasystoles 
(Table 4). Multiform ventricular extrasystoles. These were 
seen at baseline in 209 (58.4%) of 358 patients allocated to 
oxprenolol as compared with 237 (62.7%) of 378 patients 
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Figure 1. Mean heart rate of placebo-treated and oxprenolol-treated 
patients at five predetermined times in the 12 months after myo•
cardial infarction. Mean heart rate is based on the total number of 
QRS complexes within three 8 hour periods (6 AM to 2 PM, 2 PM 
to \0 PM, \0 PM to 6 AM), Evaluation "on treatment (before 
withdrawal from study medication), " For total numbers of patients 
see Table 5, bpm = beats per minute, 
allocated to placebo, Ten days after randomization, this 
proportion was almost unchanged, After 3 and 6 months, 
however, only 47.4 and 42,7%, respectively, of patients in 
the oxprenolol group had multiform ectopic beats in contrast 
to 59,7 and 57,9%, respectively, of patients in the placebo 
group (z > 2,81), Twelve months after myocardial infarc•
tion, the incidence of multiform ventricular extrasystoles in 
the oxprenolol-treated group increased again (Fig, 3), Anal•
ysis on an explicative basis, that is, considering only patients 
not withdrawn from study medication, revealed a strikingly 
similar result. 
Ventricular bigeminy, This was documented in 137 
(18,6%) of 736 patients at baseline, At no time was a sig•
nificant difference assessed between the treatment groups, 
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Figure 2. Percent of patients with different frequencies of ven•
tricular extrasystoles (VES) per hour from 24 hour electrocardio•
graphic recordings in the two treatment groups during the I year 
follow-up period evaluated on the "intention to treat" basis, Val•
ues at the top of each bar indicate percent of patients within the 
defined interval of ventricular extrasystole frequency, For total 
number of patients see Table 4. 
Ventricular couplets. These were detected in 234 (31. 8%) 
of 736 baseline 24 hour electrocardiograms (29,6% of pa•
tients allocated to oxprenolol and 33.8% of patients allo•
cated to placebo). When adjusted for baseline differences, 
statistical analysis did not reveal any significant difference 
between the treatment groups at any time during follow-up 
study (z :s 1,94 in all instances). Almost identical results 
Table 4. Percent of Patients With Ventricular Arrhythmias on Baseline and Follow-up 24 Hour Electrocardiograms: Evaluation on 
"Intention to Treat" Basis 
Baseline Day 10 Month 3 Month 6 Month 12 
Ox PI Ox PI Ox PI Ox PI Ox PI 
No. of patients 358 378 303 329 285 290 267 285 240 259 
YES ~ 30 22.1 29.6 22.4 29.5 30.9 2X.6 26.6 27.4 20.S 21.6 
(at least in 1 
hour) (%) 
Multifonn YES (%) 5S.4 62,7 55.1 62,6 47.4 59.7* 42.7 57.9t 52.1 51.0 
Bigeminy (%) 15.9 21.2 19,5 24.0 22.1 23.1 18.7 22.8 19.6 18.1 
Couplets (%) 29.6 33.9 30.0 3S.3 30.2 34.5 26.6 34.4 26.2 29.0 
VT(%) 21.5 20.9 23.1 23.4 18.2 20.3 19.1 20.0 17.5 15.8 
Couplets or VT (%) 40.5 41.8 40.3 46.S 38.6 43.1 36.0 42.5 34.2 35.9 
*z Value = - 2.84; tz value = - 3.42. Ox = oxprenolol; PI = placebo; YES = ventricular extrasystoles; VT = ventricular tachycardia. 
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Figure 3. Percent of patients with multiform ventricular extra•
systoles (YES) evaluated on the "intention to treat" and "on 
treatment" basis. The differences between the two treatment groups 
were significant only at 3 and 6 months of follow-up (z > 2.81). 
were obtained when analysis was done for patients "on 
treatment. " 
The frequency of ventricular couplets during 24 hours 
also did not differ significantly between the two treatment 
groups (Fig. 4). More than 10 couplets/24 hours at baseline 
were observed in 5.6% of patients in the oxprenolol group 
and in 7.1 % in the placebo group. There was no significant 
change during follow-up: 4.6 versus 10.3% on day 10,7.7 
versus 7.6% after 3 months, 3.7 versus 9.5 % after 6 months 
and 4.6 versus 6.6% after 12 months. However, when re•
sults from patients not withdrawn from study medication 
were evaluated, there was at least a trend in reduction in 
the daytime prevalence of ventricular couplets in the ox•
prenolol group as compared with the placebo group. This 
trend was not observed during night time (Table 5). 
Ventricular tachycardia. This was seen in 156 (21.2%) 
of 736 patients on the 24 hour electrocardiographic baseline 
recordings (21.5% of the patients randomized to oxprenolol 
and 20.9% of those randomized to placebo). During the I 
year follow-up period, the prevalence of ventricular tachy•
cardia was almost identical in the treatment groups 
(Table 4). 
Ventricular tachycardia or ventricular couplets. These 
were observed at baseline in 40.5% of patients in the ox-
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Figure 4. Percent of patients with different numbers of ventricular 
couplets per 24 hours throughout the study in the two treatment 
groups evaluated on the "intention to treat" basis. Values at the 
top of each bar indicate the percent of patients with 0, 1, 2 to 9 
and 10 or more couplets. For total number of patients see 
Table 4. 
prenolol group and 41.8% of patients in the placebo group 
(Table 4). During 6 months of follow-up, there was a small 
but nonsignificant increase in the placebo group, while the 
incidence in the oxprenolol group decreased slightly. The 
difference between the two treatment groups was at no time 
significant. Twelve months after myocardial infarction, 34% 
in the oxprenoiol group and 36% in the placebo group still 
had episodes of ventricular tachycardia or ventricular couplets. 
Cohort follow-up. When the two cohorts of patients 
with complete series of recordings for 3 months (cohort A) 
and 12 months (cohort B) were analyzed considering the 
individual variations, no significant difference between the 
oxprenolol and placebo groups was observed. For all ar•
rhythmias evaluated, approximately the same number of 
patients showed improvement or possible prevention, wors•
ening or no change. Table 6 shows the percentages of pa•
tients in the three antiarrhythmic efficacy classes with regard 
to the occurrence of: 1) at least I hour with 30 or more 
ventricular extrasystoles, and 2) at least one couplet in 24 
hours. Thus, the weak suppressant effect on the average 
occurrence of ventricular tachyarrhythmias (Table 4) is con•
firmed by the cohort follow-up method applied. 
Discussion 
Our study demonstrated a high prevalence of frequent 
ventricular extrasystoles and complex tachyarrhythmias such 
as ventricular couplets and ventricular tachycardia in sur•
vivors of acute myocardial infarction. This result is in agree-
lACC Vol. 6, NO.5 
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Table 5. Percent of Patients With Couplets at Different Periods of the Day: Evaluation "On Treatment" 
Adjusted 
Period of Day Oxprenolol Placebo z Value* 
Baseline (n = 358) (n = 378) 
6 AM to 2 PM 19.9o/c 17.5% 0.82 
2 PM to IO PM 18.60/( 18.3% 0.12 
10 PM to 6 AM 14.6* 20.7% -2.17 
Day 10 (n = 295) (n = 323) 
6 AM to 2 PM 16.4clc 26.7* -2.33 
2 PM to 10 PM 14.70/c 21.2% -1.71 
10 PM to 6 AM 15.6% 23.90/c -2.22 
Month 3 (n = 261) (n = 265) 
6 AM to 2 PM 17.1% 18.00/( -0.08 
2 PM to IO PM 12.8% 20.2% -2.13 
10 PM to 6 AM 16.3% 15.1% 0.60 
Month 6 (n = 238) (n = 247) 
6 AM to 2 PM 14.0% 20.1% -1.69 
2 PM to 10 PM 9.9% 19.2% -2.82 
10 PM to 6 AM 13.2% 19.4% - 1.81 
Month 12 (n = 184) (n = 191) 
6 AM to 2 PM II.4O/C 16.7% - 1.32 
2 PM to 10 PM 11.00/( 15.5% - 1.23 
10 PM to 6 AM 12.7% 17.5% - 1.23 
*z Value adjusted for the presence or absence of couplets at baseline (see Methods). 
ment with the findings of others (9-11). The occurrence of 
such arrhythmias is associated with an increased mortality 
during 1 or more years of follow-up (9-12). 
Antiarrhythmic effects of beta-blocking drugs: role 
in postinfarction mortality. Potential mechanisms of beta•
receptor blocking drugs in reducing the mortality rate in 
patients with recent myocardial infarction are initially con•
sidered in relation to the known pharmacologic properties 
of beta-receptor antagonists, namely, direct antiarrhythmic 
actions and actions mediated through lessening of ischemia. 
Our study failed to demonstrate a significant antiarrhythmic 
effect of oxprenolol at a daily dose of 320 mg. There was 
only a significant reduction in the incidence of multiform 
ventricular extrasystoles 3 and 6 months after myocardial 
infarction as compared with the placebo group. This is prob-
ably without significance in relation to reduction in mor•
tality. When a maximal grading of the tachyarrhythmias 
was performed, it became evident that the increased risk of 
dying the year after acute myocardial infarction was re•
stricted to those patients who showed ventricular couplets 
or short runs of ventricular tachycardia on a 24 hour elec•
trocardiogram before hospital discharge. In patients with 
multiform ventricular extrasystoles but no ventricular tachy•
cardia or ventricular pairs at baseline (22% of the total study 
group), the I year mortality rate was low, that is, 3.7% in 
the oxprenolol group and 1.2% in the placebo group (12). 
A significant reduction in heart rate during the daytime 
proved that beta-receptor blockade was effective in patients 
receiving oxprenolol. The lack of a reduction in heart rate 
at night. a typical finding for beta-blocking drugs with in-
Table 6. Percent of Patients in the Three Antiarrhythmic Efficacy Classes With Regard to the Occurrence of Ventricular 
Extrasystoles (30 or more in 1 hour) and Couplets (at least I in 24 hours) 
No. of patients 
VES "" 30 in I hour 
Improvement or possible prevention 
Insufficient efficacy 
Worsening 
Couplets 
Improvement or possible prevention 
Insufficient efficacy 
Worsening 
VES = ventricular extrasystoIes. 
Cohort A (3 mol 
Oxprenolol Placebo 
250 256 
64.4% 64.1% 
9.0% 12.9% 
27.6% 23.1% 
59.6% 54.7% 
13.6% 15.2% 
26.8% 30.1% 
Cohort B (12 mo) 
Oxprenolol Placebo 
181 186 
51.9% 59.7% 
12.2% 14.5% 
35.9% 25.8% 
48.1% 46.2% 
16.0% 23.1% 
35.9% 30.7% 
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trinsic sympathomimetic properties (13), probably does not 
explain the overall weak antiarrhythmic efficacy of oxpren-
0101. When only the daytime prevalence of arrhythmias was 
evaluated, there was also no significant drug effect; there 
was only a trend toward reducing the prevalence of ven•
tricular couplets as compared with the placebo group 
throughout the 1 year follow-up period (Table 5). 
Beta-blocking drugs with different ancillary proper•
ties. In the Beta-Blocker Heart Attack Trial (14), a sec•
ondary prevention trial after myocardial infarction in which 
patients were assigned to either 60 or 80 mg of propranolol 
three times daily, 24 hour electrocardiographic monitoring 
was done in a random sample of 25% of the study group, 
that is, in .826 patients at baseline (5 to 21 days after hos•
pitalization) and repeated after 6 weeks of therapy (15). 
There was no further follow-up study of 24 hour electro•
cardiographic recordings. 
As compared with the Beta-Blocker Heart Attack Trial, 
the prevalence of complex tachyarrhythmias was higher in 
our study. This could in part be due to the fact that baseline 
recordings in the European Infarction Study were performed 
somewhat later after the acute infarction. In the Beta-Blocker 
Heart Attack Trial, the percent of patients having \0 or 
more ventricular extrasystoles per hour and ventricular cou•
plets or ventricular tachycardia increased from baseline to 
6 weeks later (8.1 to 25.6% in the placebo group and 7.2 
to 14.6% in the propranolol group). It was concluded that 
ventricular arrhythmias increased after hospital discharge 
and that this increase was blunted by the propranolol ther•
apy. It should be noted, however, that a large percent of 
propranolol patients still had serious ventricular arrhythmias. 
Additionally, from two recent randomized double-blind 
postinfarction metoprolol studies, only relatively weak an•
tiarrhythmic effects of beta-receptor blocking treatment were 
reported. Olsson and Rehnquist (16) observed that an in•
crease in complex ventricular extrasystoles (Lown class 3 
to 5) was counteracted by long-term treatment with 100 mg 
of metoprolol twice daily. In the metoprolol group, complex 
ventricular extrasystoles were recorded in 38% of patients 
before treatment, in 42% after 6 months of treatment and 
in 51 % after 12 months of treatment, as compared with 33, 
52 and 50% of patients, respectively, in the placebo group. 
At the same dosage, Manger Cats et al. (17) reported a 
significant decrease in the incidence of 10 or more ventric•
ular extrasystoles/30 min from 1 week to 3 months after 
discharge in the metoprolol group (46 to 31 %) as compared 
with the placebo group (51 to 49%). The prevalence of 
ventricular couplets and ventricular tachycardia, however, 
decreased in the same range in the placebo group (37 to 
28% and 14 to 11 %, respectively) as it did in the metoprolol 
group (39 to 26% and 17 to 14%, respectively). In two 
earlier placebo-controlled postmyocardial infarction studies 
with smaller numbers of patients, no antiarrhythmic efficacy 
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of propranolol or atenolol (18) nor of oxprenolol (19) was 
observed. 
The efficacy of beta-antagonists in suppressing ventric•
ular extrasystoles in patients with coronary heart disease 
was studied (20) by a double-blind, randomized, placebo 
crossover protocol with incremental dose schedule of ace•
butolol, propranolol and nadolol. The three beta-antagonists 
with varying associated properties had low efficacy in sup•
pressing ventricular extrasystoles with no difference in their 
relative potencies. 
Weak suppressant effect on ventricular tachyarrhyth•
mias. From the data just discussed, it can be concluded 
that beta-blockade has a relatively weak suppressant effect 
on ventricular tachyarrhythmias in survivors of infarction, 
irrespective of different composite pharmacologic properties 
of individual agents. Singh and Venkatesh (21) stated that, 
in general, beta-blockade has a relatively weak antiar•
rhythmic effect and does not appear to be potent in con•
trolling tachyarrhythmias except under a few conditions such 
as in patients with exercise-induced arrhythmias or the long 
QT interval syndrome. High dosages of propranolol, how•
ever, (that is, considerably higher than those used in sec•
ondary beta-blocker prevention trials) with "supra-beta•
blocking" blood levels might be more effective, probably 
due to the "membrane-stabilizing" properties of propran•
olol (22). However, side effects at high doses are common 
and usually preclude continuous use. 
Consistent with this is the finding of either no significant 
antiarrhythmic effect in some studies or a significant effect 
only on particular subgroup classes of arrhythmias in other 
studies. It is highly unlikely that such a minor effect might 
explain the observed reduction in sudden death effected by 
beta-blockade (1,2). Accordingly, in the Beta-Blocker Heart 
Attack Trial, patients with complex ventricular extrasystoles 
benefited to the same relative degree from propranolol as 
did those without this arrhythmia (23). In the European 
Infarction Study, the proportion of deaths was noted to be 
higher in the oxprenolol group as compared with the placebo 
group to the same relative degree in patients with or without 
complex ventricular extrasystoles (4,12). 
Mechanisms of the protective effect of beta block•
ade. The precise mechanisms of the salutary beta-receptor 
blocking effects are not clear, but are unlikely to be due 
only to a primary antiarrhythmic effect mediated through 
the suppression of ventricular tachyarrhythmias, although 
complex ventricular extrasystoles presumably are markers 
of cardiac electrical instability. Studies relevant to patients 
with acute ischemia may provide insights into mechanisms 
of preventing ventricular fibrillation, the most frequently 
documented cause of sudden death. In a double-blind trial 
of metoprolol (24), the prevalence of ventricular tachyar•
rhythmias was not influenced in the acute phase of myo•
cardial infarction; the occurrence of ventricular fibrillation, 
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however, was significantly reduced. Experimental investi•
gations (25,26) indicate that regional adrenergic activity 
contributes to the evaluation of ventricular fibrillation during 
myocardial ischemia. Beta-adrenergic blocking agents have 
been shown to raise the lowered ventricular fibrillation 
threshold produced by acute ischemia (26-28). They may 
prevent the oxygen-wasting effects of excess sympathetic 
discharge to the heart and reduce the severity and extent of 
ischemic injury (29). The predominant protective effect of 
beta-adrenergic blockade in survivors of myocardial infarc•
tion might be an amelioration of recurrent regional myo•
cardial ischemia, with prevention of ventricular fibrillation 
as a secondary consequence. 
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Analyzing Centres and the many nurses and medical staffs of the partic•
ipating hospitals. 
Appendix 
Of the 57 hospitals of the European Infarction Study Group (4) 
the following 33 hospitals joined the 24 hour electrocardiographic 
recording part of the study: 
Clinical Centres, West Germany. Auguste-Viktoria-Kran•
kenhaus, Berlin, V. Meyer; Berufsgenossenschaftliche Kranken•
anstalten "Bergmannsheil Bochum," Medizinische Unversitiits•
klinik, Bochum, D. Schott, W. laedicke, I. Barmeyer; 1udisches 
Krankenhaus, Berlin, D. Kolmar; Klinikum Charlottenburg der 
Freien Universitiit Berlin, Berlin, H. Schmutzler. G, Berghofer. 
D. Loos; Klinikum der Philips-Universitiit, Marburg/Lahn, A. 
Hardewig, E. Becker; Klinikum Niederberg, Velbert, H. Giinne•
wig, R. Beckmann. H. Wenzel; Klinikum Steglitz der Freien Uni•
versitiit Berlin, Berlin, R. Arntz, I. Kruck, R. Dreykluft; Kran•
kenanstalt Mutterhaus der Borromiierinnen, Trier, H. Siebner, M. 
Dietz; Krankenhaus Am Urban. Berlin. W. Dissmann, U. Berg•
mann, M. Reuter; Krankenhaus Moabit, Berlin, K.-P. Schiiren, 
H.-J. Wessel; Krankenhaus Neukblln, Berlin. J. Wagner. H.-N. 
Macha, D. Zimmermann; Krankenhaus Spandau-Hohengatow, 
Berlin, W. Herbst; Krankenhaus Oststadt, Hannover. G.M. Ei•
senbach, G. Walpurger; Kreiskrankenhaus Bad Soden, Bad Soden, 
R. Babej; Martin-Luther-Krankenhaus, Berlin, I. MUller; Medi•
zinische Hochschu/e Hannover, Hannover, P. Lichtlen. U. Godt, 
A. Kuhl; I. Medizinische Klinik Wetzlar, Wetzlar, I. GroBwendt, 
G. Wettner; Medizinische Universitiitsklinik der Ruhruniversitiit 
Bochum, Marienhospital, Herne, P. Schuster. M. Koch. H.W. 
Wiechmann; Medizinische Unversitiitsklinik Homburg/Saar, Hom•
burg/Saar. L. Bette, G. Rettig, S. Sen; St. Gertrauden-Kranken•
haus, Berlin, B. Ramdohr. W. Schoormans; St. losef-Hospital, 
Bochum, D. Rieken, G. Sabin, G. Szurawitzki; St. Marien-Kran•
kenhaus, Berlin, C. Soriano-Bazan, L. Lochmann; Stadtkranken•
haus Worms, Worms, P. Limbourg, U. Schmidt-Schaffer, W. 
lung; Stiidtische Krankenanstalten Krefeld, Krefeld, K.-D. Gros•
ser, A. Heller, D. Wollthan; Stiidtische Krankenanstalten Villin•
gen-Schwenningen, Villingen-Schwenningen, K. Lang; Stiidtisches 
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Krankenhaus Siloah, Hannover, H. Klingemann, R. Klinge, 
H.-D. Peters; Wenckebach-Krankenhaus, Berlin, H. Kuckuck, R. 
Schafer, J. Veit; Zentralkrankenhaus St. 1urgen-StraJ3e. Bremen, 
K. Pot jan , D. Saupe, R. Ebbinghaus. 
Clinical Centres, Great Britain. The Genera/Infirmary, Leeds, 
S.H. Taylor, B. Silke; Ninewells Hospita/, Dundee, J. Crooks 
(deceased), D. Maclean, I. Lightbody. I.F.B. Smith. R. Brown, 
I. Robson. B. Mitchell. 
Clinical Centres, Switzerland. Kantonsspital Winterthur, 
Winterthur, A. Hany, P. Zwicky; Stadtspital Triemli. Zurich, P. 
Wirz (deceased), P. Levis; Universitiitsspital Zurich, Zurich, W. 
Steinbrunn, R. Tartini. 
Policy Board. J. P. Boissel, Lyon: J. Crooks (deceased), Dun•
dee; W. Gebhardt, Goslar; K.D. Grosser, Krefeld; P. Lichtleil, 
Hannover; D. Maclean, Dundee (since Jan 1983); R. Schroder, 
Berlin (chairman); S.H. Taylor, Leeds; I. Wagner, Berlin; P.A. 
Hummel, Basle (nonvoting); H. Voss, Frankfurt (nonvoting). 
Review Committee. P. Armitage, Oxford; F. Bender, Miins•
ter; H. Blamer, Miinchen (to 5/81); E.H. Bock, Tiibingen; e.T. 
Dollery, London (to 5/81); F.H. Epstein, Ziirich; F. Gross, Hei•
delberg; F. Grosse-Brockhoff (deceased), Diisseldorf; H.1. Jes•
dinsky, Diisseldorf; H. Kewitz, Berlin (chairman); G. Rose, Lon•
don (to 2/8\); H.I.e. Swan, Los Angeles. 
Critical Event Committee. M. Decot. Berlin; I.R. Hampton, 
Nottingham; P. von Lowis of Menar, Holzminden; K. Morris, 
Nottingham; B. Ramdohr, Berlin; W. Thimme, Berlin; H. Voh•
ringer, Berlin. 
Coordinating Centre, Berlin. Ch. Engelbert, A. Enzian, H.1. 
Lichtenberg, H. Preugschat; R. SChroder (chairman), I. Sickel, 
U. Tietze, M. Wogenstein. I. Wunderlich. 
Data Handling and Monitoring Centre, Lyon. Y. Alamercy, 
J.P. Boissel (chairman), J.M. Destors, A. Leizorovicz. (deputy 
chairman), F. Martin. I.e. Peyrieux. B. Sanchini, J. Schbath, P. 
Schott. 
Technical Commmittee. K. Bridgman, Horsham; J.M. Des•
tors, Lyon; J. Himmelsbach, Basle; A. Leizorovizc, Lyon (chair•
man since 7/80); I. Lightbody, Dundee; A. Nelson, Leeds; H. 
Preugschat, Berlin; I. Sickel, Berlin; M. Wogenstein, Berlin; J. 
Wunderlich, Berlin (to 6/80, chairman). 
24 hour ECG Committee. D. Andresen, Berlin; K.P. Bethge, 
Hannover: E.-R. von Leitner, Berlin; J.e. Peyrieux, Lyon; R. 
Schroder, Berlin; U. Tietze, Berlin (chairman). 
24 hour ECG Analyzing Centres. Berlin I: E.-R. von Leitner, 
S. Skowronski; Berlin II: D. Andresen, P. Wilden; Hannover III: 
K.P. Bethge, I. Chibanguza, B. Degenhardt. 
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